Differences in risk factors for molecular subtypes of clear cell renal cell carcinoma.
case-control study
clear cell renal cell carcinoma
epidemiology
molecular pathology
risk factors
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
revised:
26
04
2021
received:
02
12
2020
accepted:
05
05
2021
pubmed:
1
6
2021
medline:
7
9
2021
entrez:
31
5
2021
Statut:
ppublish
Résumé
The ccA and ccB molecular subtypes of clear cell renal cell carcinoma (ccRCC) have well-characterized prognostic relevance. However, it is not known whether they possess distinct etiologies. We investigated the relationships between these subtypes and RCC risk factors within a case-control study conducted in Eastern Europe. We analyzed risk factor data for ccA (n = 144) and ccB (n = 106) cases and 1476 controls through case-only and case-control comparisons to assess risk factor differences across subtypes using logistic and polytomous regression models. We also performed a meta-analysis summarizing case-only results from our study and three patient cohorts. Patients with ccB tumors had poorer survival than those with ccA tumors and were more likely to be male (case-only odds ratio [OR] 2.68, 95% confidence interval [CI] 1.43-5.03). In case-control analyses, body mass index was significantly associated with ccA tumors (OR 2.45, 95% CI 1.18-5.10 for ≥35 vs <25 kg/m
Identifiants
pubmed: 34058014
doi: 10.1002/ijc.33701
pmc: PMC8628648
mid: NIHMS1747929
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1448-1454Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA058223
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Informations de copyright
© 2021 Union for International Cancer Control. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
Références
JAMA Oncol. 2016 May 1;2(5):664-667
pubmed: 27010573
Br J Cancer. 2016 Jan 12;114(1):76-80
pubmed: 26657656
Cancer. 2017 Jan 1;123(2):200-209
pubmed: 27861752
J Natl Cancer Inst. 2013 Dec 18;105(24):1862-70
pubmed: 24285872
Genes Cancer. 2010 Feb 1;1(2):152-163
pubmed: 20871783
Am J Epidemiol. 2018 Aug 1;187(8):1630-1641
pubmed: 29394309
PLoS One. 2015 Oct 20;10(10):e0140257
pubmed: 26484545
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Cancer Res. 2010 Aug 15;70(16):6527-36
pubmed: 20663906
Expert Rev Anticancer Ther. 2009 Jul;9(7):975-87
pubmed: 19589036
Eur Urol. 2014 Jul;66(1):77-84
pubmed: 24613583
Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):173-5
pubmed: 8049640
Cancer Cell. 2016 May 9;29(5):711-722
pubmed: 27165743
Eur Urol. 2012 Feb;61(2):258-68
pubmed: 22030119
Kidney Cancer. 2018;2(1):23-29
pubmed: 30320241
Eur J Hum Genet. 2019 Oct;27(10):1589-1598
pubmed: 31231134
Eur Urol. 2014 Nov;66(5):936-48
pubmed: 25047176
Occup Environ Med. 2017 Mar;74(4):268-274
pubmed: 27803178
Am J Epidemiol. 2013 Jun 15;177(12):1368-77
pubmed: 23624999
PLoS Genet. 2011 Oct;7(10):e1002312
pubmed: 22022277
Lancet Oncol. 2014 Aug;15(9):924-5
pubmed: 25225686
Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1326-32
pubmed: 27418270
Lancet Oncol. 2012 Dec;13(12):1192-3
pubmed: 23323277
Urol Oncol. 2016 Mar;34(3):122.e1-7
pubmed: 26546482
Nat Commun. 2017 Jun 09;8:15724
pubmed: 28598434